<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104097">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01774461</url>
  </required_header>
  <id_info>
    <org_study_id>METC12-2-038</org_study_id>
    <nct_id>NCT01774461</nct_id>
  </id_info>
  <brief_title>Ischemic Preconditioning in Endurance Athletes</brief_title>
  <official_title>Influence of Remote Ischemic Preconditioning on Cardiac Function After Endurance Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effect of remote ischemic preconditioning on
      biochemical and functional indices of cardiac function induced by a 30 km run in healthy
      trained long distance runners.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Serum concentrations of cardiac troponins</measure>
    <time_frame>6 hours, 2 hourly time intervals</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Indices of cardiac function measured by echocardiography</measure>
    <time_frame>2 hours post-exercise</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Exercise</condition>
  <arm_group>
    <arm_group_label>Sham RIC</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remote ischemic conditioning</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Remote ischemic preconditioning</intervention_name>
    <description>Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.</description>
    <arm_group_label>Remote ischemic conditioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Healthy

          -  Age between 18 and 65 years

          -  Endurance-trained (two or more training sessions per week)

        Exclusion Criteria:

          -  Not applicable
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marja van Dieijen-Visser, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Chemistry, MUMC, Maastricht, the Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>July 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
